Turn Therapeutics (NASDAQ:TTRX) Upgraded to “Strong-Buy” at Lucid Cap Mkts

Lucid Cap Mkts upgraded shares of Turn Therapeutics (NASDAQ:TTRX) to a strong-buy rating in a report published on Thursday,Zacks reports.

Other equities analysts have also issued reports about the stock. WBB Securities reaffirmed a “sell” rating and set a $10.00 target price on shares of Turn Therapeutics in a report on Monday, September 14th. Weiss Ratings cut Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. Wall Street Zen raised Turn Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, September 13th. Zacks Research upgraded Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. Finally, LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $9.00.

Turn Therapeutics Trading Down 1.9%

Shares of Turn Therapeutics stock opened at $13.26 on Thursday. The stock has a market cap of $394.99 million and a PE ratio of -45.72. The firm has a fifty day moving average price of $10.60 and a 200 day moving average price of $6.95. Turn Therapeutics has a 1 year low of $2.57 and a 1 year high of $26.50. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. Equities research analysts predict that Turn Therapeutics will post -0.4 earnings per share for the current year.

Institutional Investors Weigh In On Turn Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TTRX. Ieq Capital LLC acquired a new position in Turn Therapeutics in the 2nd quarter valued at about $1,660,000. DDFG Inc raised its position in shares of Turn Therapeutics by 34.9% during the 1st quarter. DDFG Inc now owns 70,534 shares of the company’s stock valued at $226,000 after buying an additional 18,246 shares during the period. BlackRock Inc. acquired a new position in Turn Therapeutics in the second quarter valued at approximately $282,000. Bridgewater Advisors Inc. acquired a new position in Turn Therapeutics in the second quarter valued at approximately $242,000. Finally, Jefferies Financial Group Inc. purchased a new position in Turn Therapeutics in the second quarter worth approximately $119,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.